Yes, but this is biotech investing. CLVS has 1/8th the float of ARIA, and daily volume about 1/3rd of ARIA, so there is a simple magnification to consider.
More rationally - if that is the right word - ARIA has a product on the market with sales numbers that can be used to drive any particular discussion. CLVS has 3 drug candidates - and no product sales to confuse anyone's predictions.
Still, they got what the wanted/needed, and I wish them well !
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.